Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria
Launched by LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE · Jun 13, 2007
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
In areas co-endemic for falciparum and vivax malaria incorrect differential diagnosis is always a risk. Where the recommended treatment for the two diseases is the same this presents no problem for effective treatment or clinical cure of either species. Chloroquine remains an effective treatment of choice for vivax malaria in most settings, but with the spread of chloroquine-resistant falciparum malaria across Asia, many countries now use artemisinin-based combination therapy for this species of malaria. Differential diagnostic practices, have not improved in parallel. In Afghanistan the ad...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • microscopy confirmed P. vivax mono-infection
- • age \>2 years
- • weight \>5kg
- • \>1 asexual parasite per 10 fields
- Exclusion Criteria:
- • pregnant
- • evidence of concomitant infection or serious disease
- • recent use of antimalarial drugs
- • severe malaria
- • known allergy to study drugs
About London School Of Hygiene And Tropical Medicine
The London School of Hygiene and Tropical Medicine (LSHTM) is a prestigious research institution renowned for its leadership in global health and infectious disease research. Committed to advancing public health through innovative research and education, LSHTM conducts a wide array of clinical trials aimed at improving health outcomes in diverse populations. With a multidisciplinary team of experts, LSHTM leverages cutting-edge methodologies and collaborative partnerships to address pressing health challenges, particularly in low- and middle-income countries. The institution's dedication to evidence-based solutions underscores its pivotal role in shaping health policies and practices worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Mark W Rowland, PhD
Principal Investigator
London School of Hygiene and Tropical Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials